Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, with 5-year survival below 15% and few therapeutic options beyond cytotoxic chemotherapy. At the molecular level, the disease is overwhelmingly driven by a single oncogenic event: KRAS mutation, present in more than 90% of cases.
For decades, KRAS was considered “undruggable.” Its smooth molecular surface and extreme affinity for GTP/GDP made direct pharmacological inhibition extraordinarily difficult, and this limitation became a symbol of therapeutic frustration in pancreatic cancer. That paradigm is now beginning to change.
This article reviews the recent advances that are redefining KRAS — and particularly KRAS G12D, the most common subtype in PDAC — as an actionable target. Drawing on key studies in structural biology, translational oncology, and tumor immunology, it examines how selective KRAS inhibition is reshaping the therapeutic landscape of pancreatic cancer and opening the door to a new era of precision oncology.
KRAS G12D: the dominant molecular driver
Not all KRAS mutations behave the same way. A large retrospective analysis of 803 PDAC patients examined whether different KRAS subtypes carried different biological weight — and the answer was clear (Yousef et al., npj Precision Oncology, 2024).
First, KRAS mutations as a whole were associated with poorer outcomes compared to KRAS wild-type tumors. But among all mutant subtypes, KRAS G12D stood out as particularly aggressive. Patients carrying this mutation showed shorter overall survival, higher rates of metastatic disease, and more aggressive tumor behavior overall. The hazard ratio for overall survival approached 1.7 compared to KRAS wild-type disease — an independent association that held up even after accounting for other variables.
These findings are highly relevant because they establish KRAS G12D not merely as a common mutation, but as a clinically meaningful therapeutic target linked to disease aggressiveness and progression. In this context, targeting KRAS G12D may not simply inhibit tumor proliferation — it may directly interfere with the core biological mechanisms driving PDAC lethality.
Read more about What Does Remission Mean in Pancreatic Cancer on OncoDaily.
Proving KRAS is druggable
For a long time, KRAS resisted every attempt at direct targeting. Unlike enzymes or receptor tyrosine kinases, it lacks the conventional binding cavities that small molecules typically exploit — and its smooth molecular surface and extreme affinity for GTP/GDP made pharmacological inhibition seem structurally impossible.
That changed when, through rational structural design, investigators developed compounds capable of forming a salt bridge interaction with the Asp12 residue — the defining feature of the G12D mutation. This allowed selective binding to the mutant protein and subsequent inhibition of downstream signaling (Mao et al., Cell Discovery, 2022).
The preclinical results were compelling. The compounds effectively disrupted the KRAS–CRAF interaction, suppressed MAPK signaling, reduced tumor growth in pancreatic cancer xenograft models, and showed enhanced antitumor efficacy when combined with anti–PD-1 immunotherapy.
But beyond the data, the significance of this work was conceptual. For the first time, KRAS G12D was shown to be structurally targetable, pharmacologically inhibitable, and therapeutically relevant in vivo. It directly dismantled the long-standing belief that KRAS was beyond the reach of precision medicine.
MRTX1133: from molecule to medicine
Following the structural breakthroughs described above, attention rapidly shifted toward translational application. Among the emerging KRAS G12D inhibitors, MRTX1133 has become one of the most promising agents currently under investigation.
MRTX1133 demonstrated high selectivity for KRAS G12D-mutated cells, potent inhibition of KRAS downstream signaling, significant suppression of tumor growth in PDAC models, and favorable pharmacodynamic properties. The antitumor effects observed were substantial, suggesting that KRAS G12D inhibition may indeed produce clinically meaningful tumor control (Wei et al., Clinical Cancer Research, 2024).
However, the study also revealed a critical biological insight. Tumor cells exposed to KRAS inhibition rapidly activate compensatory survival mechanisms, including alternative signaling pathway activation, adaptive metabolic responses, and cellular plasticity.
MRTX1133 therefore represents a major step forward in precision oncology for PDAC — yet it also highlights a fundamental reality of pancreatic cancer biology: KRAS inhibition alone is unlikely to be sufficient. Instead, KRAS-targeted therapy will probably function as the backbone of multidimensional combination strategies.
Rewiring tumor immunity
One of the most fascinating aspects of recent KRAS research involves its unexpected effects on tumor immunity. PDAC is traditionally considered an immunologically “cold” tumor, characterized by poor T-cell infiltration, dense stromal exclusion, and profound immunosuppression — features that largely explain why immune checkpoint inhibitors have historically failed in unselected pancreatic cancer populations.
However, KRAS G12D inhibition can profoundly alter the tumor microenvironment. Increased infiltration of CD8+ cytotoxic T cells, activation of FAS-mediated tumor killing, enhanced antigen presentation, and greater sensitivity to immune checkpoint blockade were all observed — and most importantly, durable tumor regression appeared to depend on active immune engagement (Mahadevan et al., Cancer Cell, 2023).
These findings suggest that KRAS inhibition may act not only as a direct antitumor therapy, but also as an immunological sensitizer capable of transforming PDAC into a more immunotherapy-responsive disease. This introduces a new therapeutic paradigm: KRAS inhibition may create the biological conditions necessary for successful immunotherapy.
The resistance problem
As observed with virtually all targeted therapies, resistance rapidly emerged as a major concern. Several adaptive processes were identified: reactivation of MAPK signaling through bypass pathways, feedback activation loops restoring oncogenic signaling, phenotypic plasticity and cellular adaptation, and rewiring of survival pathways (Dilly et al., Cancer Discovery, 2024).
These findings reinforce the idea that pancreatic cancer is not driven by static biology. Instead, PDAC behaves as a highly adaptive ecosystem capable of rapidly evolving under therapeutic pressure. Consequently, the future of KRAS-targeted therapy will likely depend on rational combination approaches, vertical pathway inhibition, and simultaneous targeting of adaptive mechanisms.
Read About Pancreatic Cancer Cure Rate on OncoDaily.
Metabolic vulnerability
An additional layer of complexity emerged from recent studies exploring metabolic adaptation after KRAS blockade. KRAS inhibition induces profound metabolic stress in PDAC cells, particularly increasing their dependence on autophagy as a survival mechanism (Nature, 2025).
KRAS blockade was shown to enhance autophagic flux, rendering tumor cells metabolically vulnerable. Inhibition of PIKfyve was found to disrupt this adaptive process, and combined KRAS and PIKfyve inhibition produced synergistic tumor suppression.
This work is particularly important because it reframes KRAS inhibition not as a terminal therapeutic event, but as the beginning of a new biological state. By forcing tumor cells into metabolic adaptation, KRAS inhibitors may expose previously hidden vulnerabilities that can subsequently be therapeutically exploited.
Reaching the clinic
The clinical development of MRTX1133 represents one of the most important milestones in pancreatic cancer therapeutics. An ongoing phase 1/2 trial (NCT05737706) is evaluating the safety, tolerability, and preliminary efficacy of MRTX1133 in patients with KRAS G12D-mutant solid tumors. Although mature efficacy data are not yet available, the existence of this trial alone marks a historic transition: KRAS G12D inhibition has officially entered clinical oncology.
Early clinical signals
Another promising KRAS G12D inhibitor, RMC-9805, has shown encouraging early clinical signals. Preliminary data presented at ASCO GI 2025 demonstrated early antitumor activity, significant reductions in circulating tumor DNA (ctDNA), and evidence of biological target engagement. While still preliminary, these findings provide the first indications that selective KRAS G12D inhibition may translate into tangible clinical benefit in PDAC patients.
Broadening the target
In parallel, broader pan-RAS inhibition strategies are being investigated. RMC-6236 targets multiple active RAS variants and may help overcome tumor heterogeneity, mutation diversity, and adaptive escape mechanisms. Early clinical studies have demonstrated promising activity and manageable toxicity, with phase 3 development currently ongoing.
Read more about Daraxonrasib (RMC-6236) on OncoDaily.
A multidimensional future
The evolution of KRAS-targeted therapy is fundamentally reshaping the future of pancreatic cancer treatment. Importantly, the future will likely not depend on a single therapeutic agent. Instead, successful strategies will probably require KRAS inhibition as a molecular backbone, immune modulation to enhance antitumor response, metabolic targeting to exploit adaptive vulnerabilities, and combination approaches designed to prevent resistance.
This represents a major conceptual shift: from treating pancreatic cancer as a chemotherapy-resistant disease to treating it as a biologically targetable ecosystem.
Take-home message
For decades, pancreatic cancer has symbolized the limitations of precision oncology. Today, that narrative is beginning to change.
KRAS G12D — once considered untouchable — is rapidly becoming one of the most important therapeutic targets in solid tumor oncology. However, the true significance of KRAS inhibition extends beyond a single drug or mutation. It represents the emergence of an entirely new therapeutic philosophy in pancreatic cancer: one based on molecular targeting, biological adaptation, immune modulation, and rational combination therapy.
The question is no longer whether KRAS can be targeted. The question is whether we can target it effectively enough to finally alter the natural history of pancreatic cancer.
Written by Maria Maddalena Laterza, MD, PhD
You Can Watch More on OncoDaily TV.